Upsher-Smith launches women’s health portal
MAPLE GROVE, Minn. — Upsher-Smith has launched an online portal for advanced-practice clinicians interested in women’s health, the company said.
Clinicians Corner provides nurse practitioners, physician assistants, nurses and midwives with resources and educational materials.
"Upsher-Smith recognizes the valuable role advanced-practice clinicians play in women’s health care," Upsher-Smith VP marketing Jim Hughes said. "Clinicians Corner is a trusted resource and one-of-a-kind educational community for busy clinicians, with direct, focused information tailored specifically to their practice."
Ulcerative colitis market to hit $3 billion by 2020
BURLINGTON, Mass. — The market for drugs to treat ulcerative colitis will increase from 2010’s $1.7 billion to $3 billion in 2020, according to a new report by market research firm Decision Resources.
Key factors driving the market will include uptake of Humira (adalimumab), made by Abbott and Eisai, and Simponi (golimumab), made by Johnson & Johnson and Merck, as well as drugs currently under development, like Millennium’s vedolizumab and Pfizer’s tofacitinib. Markets included in the analysis were the United States, Germany, France, Italy, Spain, Japan and the United Kingdom.
"Currently in phase-3 of development for moderate to severe ulcerative colitis, but with scant robust clinical data at present to confirm positive phase-2 results, vedolizumab and tofacitinib will likely extend the treatment algorithm by offering — for the first time — additional lines of therapy for patients with inadequate response to the [tumor necrosis factor]-alpha inhibitors," Decision Resources analyst Kathrina Quinn said.
Reports: Teva developing Type 1 diabetes drug
NEW YORK — Israeli drug maker Teva Pharmaceutical Industries is developing a protein that could offer a new way to treat Type 1 diabetes, according to published reports.
Type 1 diabetes is an autoimmune disorder in which the immune system attacks the pancreas’s beta cells, but the drug, DiaPep277, stops that from happening, according to Bloomberg.
French drug maker Sanofi originally developed the drug but later gave up on it. Teva, which is developing the drug with Andromeda Biotech, has conducted a phase-3 trial of 457 patients and is planning to start a second one with 450, Bloomberg reported.